BioCentury
ARTICLE | Clinical News

CHMP recommends Sanofi's Dupixent for atopic dermatitis

July 28, 2017 4:28 PM UTC

EMA's CHMP recommended approval of Dupixent dupilumab (REGN668, SAR231893) from Sanofi (Euronext:SAN; NYSE:SNY) to treat moderate to severe atopic dermatitis. The human mAb targeting the alpha subunit...